Abstract
Brain derived neurotrophic factor (BDNF), a member of the neurotrophin family of structurally related proteins that promote neuronal differentiation and survival during development [1, 2], is a potent modulator of synaptic plasticity [3-7]. Changes in BDNF expression, release and neuromodulatory activity, mediated by both epigenetic and posttranslational mechanisms, have been associated with many pathological conditions and developmental experiences, such as maternal deprivation and environmental enrichment. Much effort has been devoted to studying plasticity in the hippocampus, a structure traditionally associated with learning and memory, yet there is increasing empirical support for the contribution of another structure — the amygdala — to BDNF-induced changes. Because the amygdala is a critical site for emotional memory formation, and many emotional and neurodevelopmental pathologies have been linked to amygdalabased abnormalities, considerable efforts have been devoted to the characterization of its circuitry [8-11]. Here we review the role of BDNF as a biochemical integrator of convergent cellular signals, and as a central driver of neural plasticity . We conclude by emphasizing the importance of characterizing BDNF signaling cascades in behaviorally-relevant networks, to identify potential drug targets for novel therapeutic interventions.
Keywords: Brain-derived neurotrophic factor, plasticity, Learning, memory, psychopathology
Current Molecular Pharmacology
Title: Brain-Derived Neurotrophic Factor: A Dynamic Gatekeeper of Neural Plasticity
Volume: 3
Author(s): Kiriana K. Cowansage, Joseph E. LeDoux and Marie-H. Monfils
Affiliation:
Keywords: Brain-derived neurotrophic factor, plasticity, Learning, memory, psychopathology
Abstract: Brain derived neurotrophic factor (BDNF), a member of the neurotrophin family of structurally related proteins that promote neuronal differentiation and survival during development [1, 2], is a potent modulator of synaptic plasticity [3-7]. Changes in BDNF expression, release and neuromodulatory activity, mediated by both epigenetic and posttranslational mechanisms, have been associated with many pathological conditions and developmental experiences, such as maternal deprivation and environmental enrichment. Much effort has been devoted to studying plasticity in the hippocampus, a structure traditionally associated with learning and memory, yet there is increasing empirical support for the contribution of another structure — the amygdala — to BDNF-induced changes. Because the amygdala is a critical site for emotional memory formation, and many emotional and neurodevelopmental pathologies have been linked to amygdalabased abnormalities, considerable efforts have been devoted to the characterization of its circuitry [8-11]. Here we review the role of BDNF as a biochemical integrator of convergent cellular signals, and as a central driver of neural plasticity . We conclude by emphasizing the importance of characterizing BDNF signaling cascades in behaviorally-relevant networks, to identify potential drug targets for novel therapeutic interventions.
Export Options
About this article
Cite this article as:
Cowansage K. Kiriana, LeDoux E. Joseph and Monfils Marie-H., Brain-Derived Neurotrophic Factor: A Dynamic Gatekeeper of Neural Plasticity, Current Molecular Pharmacology 2010; 3 (1) . https://dx.doi.org/10.2174/1874467211003010012
DOI https://dx.doi.org/10.2174/1874467211003010012 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology Vascular Patency: A Biomarker and Clinical Target Quantified with High Resolution MRI and Novel Cellular Pathways
Current Neurovascular Research Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Structure-Activity Relationship Studies: M2 and CCR5 Receptor Antagonists
Current Topics in Medicinal Chemistry Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Bottom-Up Proteomics
Current Analytical Chemistry T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research Current Therapeutic Options for Alzheimers Disease
Current Genomics Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) A Qualitative Analysis Based on Relative Expression Orderings Identifies Transcriptional Subgroups for Alzheimer’s Disease
Current Alzheimer Research Etanercept Improves Cognitive Performance and Increases eNOS and BDNF Expression During Experimental Vascular Dementia in Streptozotocin- induced Diabetes
Current Neurovascular Research